Alexion Pharmaceuticals Inc. Reaches New 12-Month High at $135.18 (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN)’s share price reached a new 52-week high on Wednesday, AnalystRatingsNetwork reports. The company traded as high as $135.18 and last traded at $134.57, with a volume of 711,325 shares traded. The stock had previously closed at $133.17.
A number of research firms have recently commented on ALXN. Analysts at Nomura initiated coverage on shares of Alexion Pharmaceuticals in a research note to investors on Wednesday. They set a “buy” rating and a $150.00 price target on the stock. Separately, analysts at UBS AG raised their price target on shares of Alexion Pharmaceuticals from $130.00 to $150.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of Alexion Pharmaceuticals from $138.00 to $161.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $129.76.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 24th. The company reported $0.83 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 36.1% on a year-over-year basis.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.